Initiatives for Sustainability and SDGs

In order to realize our corporate philosophy: "Contribute toward the improvement of people's health and progress in society through the development of innovative products," we are committed to meeting niche medical needs with a focus on areas related to hormones (products, research, etc.), We are responding to niche medical needs with a focus on fields related to hormones (products, research, etc.).
We aim to achieve sustainable growth through research, manufacturing, and sales of ethical and veterinary pharmaceuticals, as well as research and contract hormone testing.

Specific Efforts

• A wide variety of hormonal products in the field of obstetrics and gynecology
• Pharmaceuticals for the treatment of hepatic encephalopathy, a rare disease
• Thyroid hormone preparations that have been used for about 100 years
• Highly accurate LC-MS/MS sample measurement using proprietary technology
• Health management

In order to realize a society and company free from any kind of discrimination, each of our group companies is promoting the creation of workplaces where each employee can maximize his or her abilities while protecting the dignity of each employee.
In particular, in pharmaceuticals, we contribute to improving women's quality of life by providing better pharmaceuticals, especially hormone preparations, and by supporting women's life design and reproductive health.

Specific Efforts

• Oral and emergency contraceptives
• Uterine fibroids and endometriosis agent
• Dysmenorrhea agent
• Fertility Agents
• Eclampsia control and agent
• Highly accurate steroid hormone measurement for preventive medicine and improvement of unwellness
• Location-specific medical representative system
• Telecommuting system
• Granting of annual leave in increments of hours
• Introduced pioneering hourly "child nursing care leave and nursing care leave" program
• Paid childcare leave
• Target for male employees taking childcare leave: 100%

Aiming to protect the environment and continuously reduce the environmental impact of all our business activities, we are working to reduce energy consumption, promote waste reduction and reuse, and curb air and water pollution and emissions of chemical substances.

Specific Efforts

• Promote energy conservation activities
• Reduction of greenhouse gas emissions (conversion from heavy oil to city gas)
• Establishment and operation of environmental management systems, etc.
• Reduce unit energy consumption of all group companies by 1% or more compared to the previous year

In order to maintain high quality and stable supply through research, manufacturing, and sales of ethical and veterinary pharmaceuticals, and research and contract hormone testing, we are continuously strengthening the quality assurance and safety monitoring systems at each of our group companies.

Specific Initiatives

• Ensure appropriate inventory by utilizing our own factories, contract manufacturers, and external warehouses
• Operation of quality systems in pharmaceuticals (management review with management participation)
• Steady implementation of risk management plans for ethical pharmaceuticals, etc.

In the field of livestock and fisheries, we are working to improve the productivity of livestock and fisheries products as a basis for food self-sufficiency in Japan through the sale of veterinary pharmaceuticals and feed additives under the theme of "reproduction, immunity and nutrition".
We support producers and veterinary professionals throughout Japan by providing high-purity, high-quality products using bioactive substances such as reproductive hormones and amino acids.

Specific Initiatives

• A wide variety of reproductive hormones
• Oxytocin Injection Solution for Veterinary Use
• Mixed feed (Best Balance Series), etc.

We will maintain a balance between management supervision and business execution, and ensure shareholders' rights in practice through transparent, fair, prompt, and decisive decision-making, while taking autonomous actions to achieve sustainable growth and enhance corporate value over the medium to long term, thereby contributing to the development of our group, investors, and the economy as a whole. We will contribute to the development of our Group, investors, and the economy as a whole.

Specific Initiatives

• Ensure substantial equality of shareholders
• Fostering a corporate culture and climate that respects sound business ethics
• Ensuring Transparency
• Effective supervision of directors
• Constructive dialogue with shareholders

We are working to expand our drug discovery pipeline through research alliance activities and collaboration with academia and external organizations, and by promoting R&D activities through industry-government-academia partnerships.
We are developing better medicines and medical treatments to solve issues in healthy living (e.g., QOL improvement and prevention) through hormone-related substances that have their roots in our company's history.

Specific Initiatives

• Enhancement of Testing Technology and Drug Discovery Functions in Shonan iPark through Collaboration with Other Companies
• Addition of pediatric dosage and indication for existing pharmaceuticals, etc.
• Veterinary pharmaceuticals developed from ethical pharmaceuticals